STING1 and lung carcinoma: Moreover, enthusiasm surrounding immune therapy in lung cancer has been tempered by the observation that LKB1 mutant tumors are “immune cold” exhibiting no objective response to immune checkpoint inhibitors and the ability to escape immune surveillance by silencing the STING pathway (6, 18).